Abstract P6-10-06: Metachronous Contralateral Breast Cancer (CBC) Has More Aggressive Biology and Clinical Characteristics Compared to Synchronous Bilateral Breast Cancer (BBC)

Autor: N. Apostolikas, Christos H. Papadimitriou, A. Efremidis, N. Tsoukalas, NF Pistamaltzian, Drakoulis Yannoukakos, Stamatina Demiri, E Panagopoulos, Georgios Koumakis, C. Panopoulos

Publikováno v: Cancer Research. 70:P6-10

Purpose: Bilateral breast cancer is an uncommon clinical entity. There is no specific treatment strategy and controversial issues concerning diagnostic criteria, management and classification exist. Method: In order to address some of these issues, a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::44f311f1e8898ef7bae03637c09cdc29
https://doi.org/10.1158/0008-5472.sabcs10-p6-10-06

Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.

Autor: Brown TA 2nd; Department of Surgery, Brooke Army Medical Center, Ft. Sam Houston, San Antonio, TX, USA., Mittendorf EA; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Division of Breast Surgery, Department of Surgery, Breast Oncology Program, Brigham and Women's Hospital, Dana-Farber/Brigham and Women's Hospital, Boston, MA, USA., Hale DF; Department of Surgery, Brooke Army Medical Center, Ft. Sam Houston, San Antonio, TX, USA., Myers JW 3rd; Department of Surgery, Brooke Army Medical Center, Ft. Sam Houston, San Antonio, TX, USA., Peace KM; Department of Surgery, Brooke Army Medical Center, Ft. Sam Houston, San Antonio, TX, USA., Jackson DO; Department of Surgery, Brooke Army Medical Center, Ft. Sam Houston, San Antonio, TX, USA., Greene JM; Department of Surgery, Brooke Army Medical Center, Ft. Sam Houston, San Antonio, TX, USA., Vreeland TJ; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Clifton GT; Department of Surgery, Brooke Army Medical Center, Ft. Sam Houston, San Antonio, TX, USA., Ardavanis A; Cancer Immunology and Immunotherapy Center, St. Savas Cancer Hospital, Athens, Greece., Litton JK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shumway NM; Texas Oncology PA, San Antonio, TX, USA., Symanowski J; Department of Cancer Biostatistics, Levine Cancer Institute, Charlotte, NC, USA., Murray JL; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ponniah S; Cancer Vaccine Development Laboratory, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA., Anastasopoulou EA; Cancer Immunology and Immunotherapy Center, St. Savas Cancer Hospital, Athens, Greece., Pistamaltzian NF; Cancer Immunology and Immunotherapy Center, St. Savas Cancer Hospital, Athens, Greece., Baxevanis CN; Cancer Immunology and Immunotherapy Center, St. Savas Cancer Hospital, Athens, Greece., Perez SA; Cancer Immunology and Immunotherapy Center, St. Savas Cancer Hospital, Athens, Greece., Papamichail M; Cancer Immunology and Immunotherapy Center, St. Savas Cancer Hospital, Athens, Greece., Peoples GE; Department of Surgery, Uniformed Services Health University, Bethesda, MD, USA. gpeoples@cancerinsight.com.; Cancer Vaccine Development Program, 1305 East Houston Street, San Antonio, TX, 78205, USA. gpeoples@cancerinsight.com.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2020 Jun; Vol. 181 (2), pp. 391-401. Date of Electronic Publication: 2020 Apr 22.

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.

Autor: Mittendorf EA; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA eamitten@mdanderson.org., Ardavanis A; Cancer Immunology and Immunotherapy Center, St Savas Cancer Hospital, Athens, Greece., Symanowski J; Department of Cancer Biostatistics, Levine Cancer Institute, Charlotte., Murray JL; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston., Shumway NM; Department of Hematology/Oncology, Brooke Army Medical Center, Ft Sam Houston Cancer Vaccine Development Laboratory, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda., Litton JK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston., Hale DF; Department of Surgery, Brooke Army Medical Center, Ft Sam Houston., Perez SA; Cancer Immunology and Immunotherapy Center, St Savas Cancer Hospital, Athens, Greece., Anastasopoulou EA; Cancer Immunology and Immunotherapy Center, St Savas Cancer Hospital, Athens, Greece., Pistamaltzian NF; Cancer Immunology and Immunotherapy Center, St Savas Cancer Hospital, Athens, Greece., Ponniah S; Cancer Vaccine Development Laboratory, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda., Baxevanis CN; Cancer Immunology and Immunotherapy Center, St Savas Cancer Hospital, Athens, Greece., von Hofe E; Antigen Express, Worcester., Papamichail M; Cancer Immunology and Immunotherapy Center, St Savas Cancer Hospital, Athens, Greece., Peoples GE; Cancer Vaccine Development Program, San Antonio Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, USA.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2016 Jul; Vol. 27 (7), pp. 1241-8. Date of Electronic Publication: 2016 Mar 30.